AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline

AnaptysBio (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced top-line proof-of-concept data from an interim analysis of an ongoing Phase 2a trial in adult patients with peanut allergy.

As quoted in the press release:

“Peanut allergy is a serious medical condition often associated with other food allergies, atopic dermatitis and asthma,” said Stephen Tilles, M.D., Clinical Professor at the University of Washington, Executive Director of Asthma Inc Clinical Research Center, Immediate Past President of the American College of Allergy, Asthma, and Immunology (ACAAI) and an investigator in this Phase 2a clinical trial.  “The data from this trial suggest that ANB020 may be a promising new paradigm for peanut allergy patients.  Patients suffering from this debilitating condition are motivated to pursue new treatments that provide protection from the life-threatening symptoms of accidental peanut exposure.”

Click here to read the full press release.